Drug intelligence / Profile preview

CD96 antibody

Development stage: Unknown
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal, Subcutaneous, Intrapulmonary

Overview

CD96 antibody is an immuno-oncology antibody that targets CD96. It entered Phase I clinical trials during a drug discovery collaboration between GSK and 23andMe, which was extended in January 2022.

Other names: CD96 antibodyCD-96 antibodyCD 96 antibodyanti-Tactile antibodyCD96 inhibitorCD-96 inhibitorCD 96 inhibitorCD96 antagonistCD-96 antagonistCD 96 antagonist

Targets

CD96 (T-cell surface protein tactile)

Beyond the preview

Go deeper on CD96 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD96 antibody.

Explore the full profile